Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | F12 | P00748 | 4/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22355302 | 0.91 | GPR119 (0.41) | EPHX1GPR119EPHX2HPGDF12 | |
| SCHEMBL3983381 | 0.79 | EPHX1 (0.41) | EPHX1PDE4BGPR119HPGDALDH1A1 | |
| SCHEMBL14964702 | 0.77 | PDE4B (0.49) | EPHX1PDE4BGPR119SMN1; SMN2HPGD | |
| SCHEMBL20166149 | 0.77 | F12 (0.61) | F12 | |
| SCHEMBL20166147 | 0.77 | F12 (0.61) | F12 | |
| SCHEMBL8221976 | 0.76 | PDE4B (0.48) | EPHX1PDE4BGPR119SMN1; SMN2HPGD | |
| SCHEMBL13390607 | 0.76 | PDE4B (0.48) | EPHX1PDE4BGPR119SMN1; SMN2HPGD | |
| SCHEMBL1445046 | 0.76 | PDE4B (0.48) | EPHX1PDE4BGPR119SMN1; SMN2HPGD | |
| SCHEMBL30453781 | 0.76 | PDE4B (0.48) | EPHX1PDE4BGPR119SMN1; SMN2HPGD | |
| SCHEMBL13390675 | 0.76 | PDE4B (0.48) | EPHX1PDE4BGPR119SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541381-B1 | INHIBITORS OF FACTOR XIIA | MERCK SHARP & DOHME LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11014920-B2 | Factor XIIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200262831-A1 | Factor XIIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014920-B2 | Factor XIIa inhibitors | F11, F13B, SERPINC1 | EPHX1 208/4885PDE4B 912/4885GPR119 3130/4885 |
| US-20200262831-A1 | Factor XIIa Inhibitors | F11, F13B, SERPINC1 | EPHX1 208/4885PDE4B 912/4885GPR119 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.